Modified pectins, compositions and methods related thereto
View Patent ↗The present invention provides compositions of modified pectin and methods for preparing and using them.
1. A method for treating chronic inflammation, comprising administering to a patient in need thereof a biologically active pectin made by a process comprising: (a) passing an aqueous solution comprising 1-20 mg/mL pectin and 7.5%-25% w/w ethanol through a tangential flow filter with a pore size of less than 1.0 μm to yield a permeate comprising a biologically active pectin having an average molecular weight from 10 kDa to 250 kDa; and (b) collecting said biologically active pectin.
2. A method for treating chronic inflammation, comprising administering to a patient in need thereof a partially de-esterified pectin made by a process comprising: (a) treating a first aqueous solution comprising 1-20 mg/mL pectin with acid, base, or both, to partially de-esterify the pectin, (b) neutralizing the first solution to yield a second aqueous solution comprising partially de-esterified pectin, (c) combining the second aqueous solution with sufficient ethanol to result in a solution comprising 7.5%-25% w/w ethanol, (d) passing the resulting solution through a tangential flow filter with a pore size of less than 1.0 μm to yield a permeate comprising partially de-esterified pectin having an average molecular weight from 10 kDa to 250 kDa, wherein the degree of esterification in the partially de-esterified pectin is between 10% and 60%, and (d) collecting said partially de-esterified pectin.
3. A method for treating chronic inflammation, comprising administering to a patient in need thereof a biologically active pectin made by a process comprising: (a) passing an aqueous solution comprising 1-20 mg/mL pectin and 7.5%-25% w/w ethanol through a tangential flow filter with a pore size of 0.1 μm to 1.0 μm to yield a permeate, wherein said permeate comprises a biologically active pectin having an average molecular weight from 10 kDa to 250 kDa; and (b) collecting said biologically active pectin.
4. A method for treating chronic inflammation, comprising administering to a patient in need thereof a partially de-esterified pectin made by a process comprising: (a) treating a first aqueous solution comprising 1-20 mg/mL pectin with acid, base, or both, to partially de-esterify the pectin, (b) neutralizing the first aqueous solution to yield a second aqueous solution comprising partially de-esterified pectin, (c) passing a third aqueous solution comprising the second aqueous solution and 7.5%-25% w/w ethanol through a tangential flow filter with a pore size of 0.1 μm to 1.0 μm to yield a permeate comprising partially de-esterified filtered pectin having an average molecular weight from 10 kDa to 250 kDa, wherein the degree of esterification in the partially de-esterified pectin is between 10% and 60%, and (d) collecting said biologically active partially de-esterified pectin.
5. The method of claim 1 , wherein the pore size is about 0.2 μm.
6. The method of claim 1 , wherein the aqueous solution has a pectin concentration of 1 to 10 mg/mL.
7. The method of claim 1 , wherein the aqueous solution has a pH in the range of 2.5 to 7.5.
8. The method of claim 1 , wherein the average molecular weight of the pectin is in a range of 50 kDa-200 kDa.
9. The method of claim 1 , wherein the biologically active pectin binds galectin-3 and modifies the interaction of galectin-3 with monocytes or macrophages.
10. The method of claim 1 , wherein the aqueous solution comprises 10%-20% w/w ethanol or 15%-25% w/w ethanol.
11. The method of claim 1 , wherein the pectin in the aqueous solution is citrus pectin.
12. The method of claim 1 , wherein the pectin in the aqueous solution has one or more mannose subunits.
13. The method of claim 12 , wherein the pectin in the aqueous solution has galactose side chains.
14. The method of claim 13 , wherein the pectin in the aqueous solution has a galactose content of greater than or equal to 5%.
15. The method of claim 13 , wherein the galactose side chains are linked to one or more of the mannose subunits.
16. The method of any one of claim 1 , wherein the pectin is formulated for oral delivery.
17. The method of any one of claim 1 , wherein the pectin is formulated for parenteral delivery.
18. The method of claim 2 , wherein the pore size is about 0.2 μm.
19. The method of claim 2 , wherein the first aqueous solution has a pectin concentration of 1 to 10 mg/mL.
20. The method of claim 2 , wherein the first aqueous solution has a pH in the range of 2.5 to 7.5.
21. The method of claim 2 , wherein the average molecular weight of the biologically active partially de-esterified pectin is in a range of 50 kDa-200 kDa.
22. The method of claim 2 , wherein the partially de-esterified pectin binds galectin-3 and modifies the interaction of galectin-3 with monocytes or macrophages.
23. The method of claim 2 , wherein the second aqueous solution is combined with sufficient ethanol to yield a solution comprising 10%-20% w/w ethanol or 15%-25% w/w ethanol.
24. The method of claim 2 , wherein the pectin in the first aqueous solution is citrus pectin.
25. The method of claim 2 , wherein the pectin in the aqueous solution has one or more mannose subunits.
26. The method of claim 25 , wherein the pectin in the aqueous solution has galactose side chains.
27. The method of claim 26 , wherein the pectin in the aqueous solution has a galactose content of greater than or equal to 5%.
28. The method of claim 26 , wherein the galactose side chains are linked to one or more of the mannose subunits.
29. The method of claim 3 , wherein the pectin in the aqueous solution has one or more mannose subunits.
30. The method of claim 29 , wherein the pectin in the aqueous solution has galactose side chains.
31. The method of claim 30 , wherein the pectin in the aqueous solution has a galactose content of greater than or equal to 5%.
32. The method of claim 30 , wherein the galactose side chains are linked to one or more of the mannose subunits.
33. The method of claim 1 , wherein the average molecular weight of the pectin is in a range of 80 kDa-150 kDa.
34. The method of claim 1 , wherein the average molecular weight of the pectin is in a range of 70 kDa-150 kDa.
35. The method of claim 1 , wherein the average molecular weight of the pectin is in a range of 80 kDa-100 kDa.
36. The method of claim 2 , wherein the average molecular weight of the biologically active partially de-esterified pectin is in a range of 80 kDa-150 kDa.
37. The method of claim 2 , wherein the average molecular weight of the biologically active partially de-esterified pectin is in a range of 70 kDa-150 kDa.
38. The method of claim 2 , wherein the average molecular weight of the biologically active partially de-esterified pectin is in a range of 80 kDa-100 kDa.